SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IMRX

Immuneering Corp (IMRX)

NASDAQ: IMRX · Real-Time Price · USD
Healthcare · Biotechnology
$3.52-$0.19 (-5.12%)
 
Market cap
$228M
Insider Score
Analyst consensus
Market Cap$227.97M-44.6%
Revenue (ttm)n/a
Net Income-$66.50M
EPS-$0.92
Shares Out64.76M
PE Ration/a
Forward PE-2.14
Dividendn/a
Ex-Dividend Daten/a
Volume1,019,933
Open$3.70
Previous Close$3.71
Day's Range$3.48 - $3.78
52-Week Range$3.35 - $8.48
Beta0.46
AnalystsStrong Buy
Price Target$17.00(+382.95%)
Earnings DateOct 29, 2026

About IMRX

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Address
245 Main Street, Cambridge, MA, 02142, United States
Market Cap
228 million
Employees
65
Industrial Classification
Biotechnology

Immuneering Corp Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
69th Percentile Overall Score
IMRX InsiderScore:80 / 99

Immuneering Corp scored higher than 69% of companies evaluated by InsiderBuying, and ranked 24th out of 101 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Immuneering Corp bought $89.5K of stock across 1 purchase in the last 90 days, the largest of them $89.5K.

Stake Increase

The average purchase added about 11% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$89.50K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-5.12%
5 Days
-3.56%
1 Month
-1.95%
6 Months
-27.72%
1 Year
-44.57%

$IMRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IMRX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IMRX's directors and management

Net Shares Purchased by Insiders−30k−15k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IMRX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New IMRX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IMRX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from IMRX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
80.42
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
60

News check: Multiple conference presentations and positive pancreatic cancer data support clinical progress, though no major catalyst or analyst action provided.

Recent Insider Activity

Buys
1
Sells
0
Buy Value
$89.50K
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.25%
SBIOALPS Medical Breakthroughs ETF0.15%
IWCiShares Micro-Cap ETF0.05%
IBBQInvesco Nasdaq Biotechnology ETF0.02%
IBBiShares Biotechnology ETF0.01%
BIBProShares Ultra Nasdaq Biotechnology0.01%

Weight is the stock’s share of each fund’s holdings.